Current Complaints | Help Center| Subscribe

Recent:

Data for the month ending - Aug, 2026

Sr. No.	Received from	Pending at the end of last month	Received	Resolved*	Total Pending #	Pending complaints >3months	Average Resolution time^ (in days)
1	Directly from Investors	0	0	0	0	0	0
2	SEBI (SCORES)	0	0	0	0	0	0
3	Other Sources (if any)	0	0	0	0	0	0
	Grand Total	0	0	0	0	0	0

^ Average Resolution time is the sum total of time taken to resolve each complaint in days, in the current month divided by total number of complaints resolved in the current month.

Trend of Monthly Disposal of Complaints

Sr. No.	Month	Carried forward from previous month	Received	Resolved*	Pending#
1	Jun, 2026	0	0	0	0
2	Jul, 2026	0	0	0	0
3	Aug, 2026	0	0	0	0
	Grand Total	0	0	0	0

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the month.

Trend of Annual Disposal of Complaints

Sr. No.	Fin. Year	Received	Resolved*
1	2021-22	1	1
2	2022-23	1	1
3	2023-24	0	0
4	2024-25	0	0
	Grand Total	2	2

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the year.

Glenmark Pharmaceuticals reports 21% rise in Q3 consolidated net profit

Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 532296 | NSE: GLENMARK

13 Feb 2023 Evaluate

Glenmark Pharmaceuticals has reported results for third quarter ended December 31, 2022 (Q3FY23).

The company has reported fall of 21.52% in its net profit at Rs 430.50 crore for Q3FY23 as compared to Rs 548.52 crore for the same quarter in the previous year. However, total income of the company marginally increased by 0.06% at Rs 2251.20 crore for the quarter under review as compared Rs 2249.80 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported rise of 21.28% in its net profit at Rs 290.76 crore for Q3FY23 as compared to Rs 239.75 crore for the same quarter in the previous year. Total income of the company increased by 11.07% to Rs 3540.27 crore for the quarter under review as compared to Rs 3187.31 crore for the same quarter in the previous year.

Peers

Company Name	CMP
Sun Pharma. Inds.	1783.25
Dr. Reddys Labs.	1202.40
Cipla	1329.50
Lupin	2007.10
Zydus Lifesciences	1154.00
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.